Acquisition intelligence · WATCH
Galactose, intravenous
Diabetic Macular Oedema
Registry context is not proof of global abandonment, clinical benefit or availability.
Human Signal
UNKNOWNConfidence UNKNOWNDrivers and unknowns
Human Efficacy: UNKNOWN
Not assessed
Exposure: UNKNOWN
Not assessed
Target Engagement: UNKNOWN
Not assessed
Indication Relevance: UNKNOWN
Not assessed
Contradictory Evidence: UNKNOWN
Not assessed
Cheap Truth
UNKNOWNConfidence UNKNOWNDrivers and unknowns
Patient Access: UNKNOWN
Not assessed
Objective Endpoint: UNKNOWN
Not assessed
Endpoint Duration: UNKNOWN
Not assessed
Sample Burden: UNKNOWN
Not assessed
Dosing Monitoring: UNKNOWN
Not assessed
Sites Procedures: UNKNOWN
Not assessed
Acquirability
UNKNOWNConfidence UNKNOWNDrivers and unknowns
Current Holder: UNKNOWN
Not assessed
Chain Of Title: UNKNOWN
Not assessed
Ip Runway: UNKNOWN
Not assessed
Data Transfer: UNKNOWN
Not assessed
Cmc Transfer: UNKNOWN
Not assessed
Seller Motivation: UNKNOWN
Not assessed
MODEL INFERENCE Principal risk: Public summaries may not translate into transferable, decision-quality evidence for the proposed product.
01 · Decision framing
Executive Thesis
MODEL INFERENCEResolve evidence transferability before committing to development; this is diligence triage, not a purchase recommendation.
Resolve explicit concerns and missing evidence before prioritizing capital.
Confidence UNKNOWN. Unknown inputs remain unresolved; this is a diligence lead, not a buy recommendation.
Why It Stopped
MODEL INFERENCECannot determine · Non-biological stopping reasons warrant review only if separate human evidence remains plausible; they do not prove the drug works.
No sufficient increase in plasma osmolarity by galactose (one patient included)
SOURCE FACT NCT00427986 · 2007-06-26 · trial-scoped stopping reason
Human Evidence
Publication existence does not establish benefit or safety. Treatment relationship, human context, indication and endpoint relevance must all be checked.
UNKNOWN No reviewed treatment-specific human conclusion is established on this page.
Inspect original evidence and attribution recordsWhat Prior Work Still Counts
SOURCE FACT 1 cached trial contexts, which may include comparator, combination or other indication use.
UNKNOWN Raw-data transferability, product equivalence and accepted reuse require scoped review. Trial completion alone does not establish reusable development.
Subscription access opens scoped analysis tools; it does not resolve missing evidence, prove ownership or guarantee a usable budget.
Unlock Full Acquisition AnalysisDevelopment Restart
Where the asset responsibly restarts depends on the exact product, indication, reusable package and regulator position.
Scoped analysis requires subscription access. Missing evidence remains UNKNOWN. View access options
Cost-to-Truth
The next dollar should buy a decision. A useful budget defines the question, decisive endpoint, operational burden and stop/go criteria.
Scoped analysis requires subscription access. Missing evidence remains UNKNOWN. View access options
Rights / Acquisition Path
UNKNOWNCurrent legal clearance is UNKNOWN. Sponsor is not owner; patent assignee is not automatically commercial controller. A corporate acquisition does not establish asset title.
Scoped analysis requires subscription access. Missing evidence remains UNKNOWN. View access options
Transaction Economics
Historical development spend is sunk cost, not an acquisition valuation.
Scoped analysis requires subscription access. Missing evidence remains UNKNOWN. View access options
Competing Interest
UNKNOWNNo comprehensive current competing-interest review is established. Absence of a stored signal does not mean absence of buyers.
Walk-Away Conditions
MODEL INFERENCE- No usable or transferable data rights
- Unresolved material safety signal
- Unbridgeable product or manufacturing change
What Would Change Our Mind
MODEL INFERENCETransferable source data, a documented current rights path and a feasible decisive experiment could justify further diligence. Material safety, title or feasibility failures could end it.
Sources
SOURCE FACTCached source dates are not confirmation that a historical claim remains current. Source conflicts: 0. Confidence and scope stay attached to the evidence.
Registry records and source dates
NCT00427986 · TERMINATED · 2007-06-26 · Diabetic Macular Oedema
Why this survived
MODEL INFERENCE: a source-backed stopping observation deserves review; it has not necessarily passed buyer qualification.
Next Best Diligence Question
Resolve the first unassessed or concerning gate component before capital allocation.
Why it matters: this gap can change whether further work is justified. Seek scoped human outcomes and transferable rights/data from official registry results, publications and executed agreements. The decision may remain UNKNOWN.
Evidence completeness — not confidence
Human Signal: 0 / 5 components adjudicated
Cheap Truth: 0 / 6 components adjudicated
Clean Rights: 0 / 6 components adjudicated
Market Pull: 0 / 5 components adjudicated
Fatal flaw
Unknown — absence of a fatal rating is not safety clearance.
See the scoped failure evidence and principal risks above.
What would change our mind?
DILIGENCE CRITERIA: attributable benefit, transferable rights and a feasible next study would increase conviction; adequate negative results, material safety harm or inaccessible essential rights would weaken it. These are questions, not observed facts.